MAIL MAN

[righty]

Synta Pharmaceuticals: Stay Away from This Hopeless Pharma Stock
Fri, December 11, 2009 10:20:35 AMFrom: Penny Sleuth

--------------------------------------------------------------------------------

The Penny Sleuth Features: Penny Stocks, Options and High-Growth Opportunities!


Editor’s Note: Today, new contributor Steve Alexander is here to share his analysis on this troubled pharma play…

Synta Pharmaceuticals: Stay Away from
This Hopeless Pharma Stock
By Steve Alexander
December 11, 2009


Investors are understandably eyeing pharmaceutical stocks right now — the pharma industry has returned an average of 5 times more than the S&P 500 in the last quarter. And some of the biggest growth has been in the small-cap space. But while most investors clamor to snatch up shares of drug makers, one pharma stock you should avoid is sending the wrong signal. Here’s why you shouldn’t buy shares of Synta…

Synta Pharmaceuticals (NASDAQ: SNTA) is a development-stage bio-pharmaceutical company. Currently the company has 3 candidates past pre-clinical studies. STA-9090 is what is known as an Hsp90 inhibitor, which for those of us without medical degrees means that the drug is targeted to prevent and possibly reduce the spread of cancerous tumors.

This drug is just now entering Phase 2 clinical trials. The second drug is Apilimod, a treatment targeting rheumatoid arthritis, also just entering Phase 2. Finally there is elesclomol, an “oxidative stress inducter” for cancer treatment, specifically metastatic melanoma, a form of skin cancer. Synta has other compounds under development, but as most are in pre-clinical stages, there is no reason to discuss them at this point.

********************************

You Could Get Rich Investing in Scientifically Selected Penny Stocks

My CXS Money-Multiplier Strategy helps me find enormous gains. And I’ve made it incredibly easy. I do all the work, telling you when to buy and sell. The profits can be awesome. You’ll HATE Yourself if You Miss This One!

********************************

Elesclomol is a sad story for Synta, despite it being the reason why the stock perked up on my Magic Formula radar. The company entered a joint development agreement with GlaxoSmithKline (NYSE: GSK) in 2007, and the drug progressed well through Phase 1 and 2 clinical trials, and Phase 3 (the final stage before submission) was scheduled to complete in 2009. In February, Synta received results that showed elesclomol was producing lower overall survival rates than no treatment, causing the FDA to put the drug on clinical hold. Glaxo saw this result as a death sentence for the compound, and terminated the joint venture in September.

With the termination, Synta recognized nearly $115 million of previously deferred revenue on the income statement in the just-completed Q3 (deferred revenue is cash already received but not yet recorded on the income statement). This has pushed the company’s trailing 12-month operating profits way, way past anything sustainable and has led to an earnings yield over 60%, and return on capital over 1,300%!

Clearly, this is a one-time event and not something we can rely on.

Looking at Synta’s results absent this windfall, they are grim. The company started operations in 2001 and has never produced any marketable drugs. The only way they continue to operate is through financing such as the 2007 IPO and preferred stock offerings, as well as a few minor licensing milestone payments and government grants. In 2005 and 2006, there was no revenue at all!

As a result, Synta has been unprofitable for its entire existence, accumulating a deficit of over $400 million dollars. With elesclomol a failure, the future is even darker. Speculating on anything before Phase 3 is risky business.

The disappointing thing is that until this one-time payment falls 4 quarters behind, it’s likely that Synta will continue to occupy a space in stock screens as a stock worth looking at. Avoid this one at all costs — it might even make an interesting short candidate right now: typical annual cash burn is near $50 million and that’s about all the company has left in its coffers. (For more about this strategy, click here.)

Don’t get burned by this unattractive pharma stock…

Sincerely,
Steve Alexander
MagicDiligence.com

P.S.: You could average 52% gains every 3 days in the world’s most liquid, recession proof market. I’m talking about FOREX… You do no work. You never study a chart. But you could rake in fast, repeatable profits. Click here to learn how…



--------------------------------------------------------------------------------



Learn How You Could Turn $200 Into $1.2 Million!

How One Pink Stock Gained 113% in Less Than Two Months

Investing in Penny Stocks

What Is Technical Trading

Investing in the Over the Counter Bulletin Board (OTCBB)


--------------------------------------------------------------------------------

Follow the Penny Sleuth on Twitter, here.



The Penny Sleuth, a free e-letter, offers independent news and commentary on small cap stocks, options and high growth opportunities.

Are you having trouble receiving your Penny Sleuth? You can ensure its arrival in your mailbox by: Whitelisting Penny Sleuth.


--------------------------------------------------------------------------------

To end your Penny Sleuth e-mail subscription, click: Unsubscribe.


--------------------------------------------------------------------------------

Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

© 2009 Agora Financ ial, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the World Wide Web), in whole or in part, is strictly prohibited without the express written permission of Agora Financial, LLC. 808 Saint Paul Street, Baltimore MD 21202.